Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models

benzinga.com/general/biotech/25/05/45403640/exclusive-channel-therapeutics-touts-positive-efficacy-results-for-eye-treatment-potential-in-mul

Channel Therapeutics Corporation (NYSE:CHRO) announced on Wednesday that it has achieved its predefined endpoints in two preclinical animal models for eye drop formulations (CT2000) for acute ocular and chronic ocular surface pain commonly associated with dry eye disease.
"We are very…

This story appeared on benzinga.com, 2025-05-14 11:59:12.
The Entire Business World on a Single Page. Free to Use →